Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9DC9

Mtb GuaB dCBS in complex with inhibitor compound 5

This is a non-PDB format compatible entry.
Summary for 9DC9
Entry DOI10.2210/pdb9dc9/pdb
DescriptorInosine-5'-monophosphate dehydrogenase, INOSINIC ACID, (3P)-3-(4-chloro-1H-imidazol-2-yl)-5-[(1R)-1-{[(3M)-3-(1H-pyrazol-5-yl)phenyl]oxy}ethyl]pyridine, ... (4 entities in total)
Functional Keywordsguab, impdh, tuberculosis, oxidoreductase
Biological sourceMycobacterium tuberculosis
More
Total number of polymer chains1
Total formula weight44167.53
Authors
Harris, S.F.,Wu, P. (deposition date: 2024-08-25, release date: 2024-11-27, Last modification date: 2025-01-29)
Primary citationZhou, Y.,Aliagas, I.,Wang, S.,Li, C.S.,Liu, Z.,Bowman, C.M.,Burdick, D.J.,Clark, K.R.,Dening, T.J.,Flygare, J.,Ganti, A.,Girgis, H.S.,Hanan, E.J.,Harris, S.F.,Hu, C.,Kapadia, S.B.,Koehler, M.F.T.,Lai, T.,Liang, J.,Liu, X.,Ma, F.,Mao, J.,Nicolai, J.,Sims, J.,Unhayaker, S.,Wai, J.,Wang, X.,Wu, P.,Xu, Y.,Yen, C.W.,Zhang, R.,Elfert, T.F.,Tan, M.W.,Kofoed, E.M.,Crawford, T.D.
Discovery of potent dihydro-oxazinoquinolinone inhibitors of GuaB for the treatment of tuberculosis.
Bioorg.Med.Chem.Lett., 117:130026-130026, 2025
Cited by
PubMed Abstract: Tuberculosis is the leading cause of death from an infectious disease, and is caused by Mycobacterium tuberculosis (M.tb). More than 1 billion people worldwide are thought to harbor an M.tb infection. The multidrug therapy that represents the current standard of care requires a minimum of four months of dosing and drug resistant Mycobacterium tuberculosis treatment regimens are significantly longer. Inosine-5'-monophosphate dehydrogenase (GuaB) is the enzyme that performs the rate-limiting step in de novo guanine nucleotide biosynthesis that is critical for growth and viability of bacteria including M.tb. The development of a novel antibiotic that inhibits GuaB could combine with existing therapies in novel ways and thereby contribute to effective therapeutic regimens for the treatment of tuberculosis. Here we describe the discovery of structurally distinct small molecule GuaB inhibitors that are potent against M.tb H37Ra and H37Rv strains and have desirable safety and AMDE profiles.
PubMed: 39536836
DOI: 10.1016/j.bmcl.2024.130026
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.6 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon